ArticleFrontiers in pharmacology2026
VB-84922 is a small molecule that inhibits ER-to-golgi transport of SREBPs-SCAP complexes.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sterol response element binding proteins (SREBPs), SREBP-1a/c and SREBP-2, are sterol-regulated transcription factors that control the expression of cholesterol and fatty acid-raising genes. Elevated expression of SREBPs has been linked to increased morbidity and mortality rates associated with conditions including obesity, cancer, and cardiovascular disease. Therefore, the development of new therapeutics to inhibit SREBP activity may be beneficial for treating various diseases associated with altered lipid levels. In their inactive state, SREBPs remain sequestered in the ER membrane in a complex with SREBP cleavage activating protein (SCAP) and one of two ER-anchoring proteins, Insig-1 or Insig-2. Activation proceeds through dissociation of SREBP/SCAP from Insigs, SCAP-assisted translocation to the Golgi, proteolytic membrane release and nuclear import. We employed a high-throughput enzyme complementation assay to identify inhibitors of SREBP-2 translocation to the nucleus, resulting in the identification of VB-84922 having an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.